X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11274) 11274
Book Review (1923) 1923
Publication (804) 804
Newsletter (475) 475
Newspaper Article (78) 78
Book Chapter (53) 53
Conference Proceeding (46) 46
Magazine Article (45) 45
Dissertation (9) 9
Book / eBook (6) 6
Government Document (4) 4
Trade Publication Article (4) 4
Report (2) 2
Presentation (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9619) 9619
female (7799) 7799
humans (7737) 7737
tamoxifen (7232) 7232
oncology (4210) 4210
breast neoplasms - drug therapy (4165) 4165
breast cancer (4147) 4147
middle aged (3333) 3333
animals (3032) 3032
tamoxifen - administration & dosage (2933) 2933
tamoxifen - therapeutic use (2488) 2488
aged (2467) 2467
adult (2335) 2335
cancer (2258) 2258
tamoxifen - pharmacology (2161) 2161
breast neoplasms - pathology (1943) 1943
postmenopausal women (1812) 1812
antineoplastic combined chemotherapy protocols - therapeutic use (1631) 1631
estrogen (1618) 1618
male (1545) 1545
care and treatment (1442) 1442
research (1428) 1428
mice (1403) 1403
antineoplastic agents, hormonal - therapeutic use (1334) 1334
chemotherapy (1327) 1327
treatment outcome (1245) 1245
rats (1241) 1241
therapy (1203) 1203
women (1132) 1132
chemotherapy, adjuvant (1115) 1115
tamoxifen - adverse effects (1090) 1090
health aspects (1048) 1048
drug therapy (1043) 1043
pharmacology & pharmacy (989) 989
antineoplastic agents, hormonal - administration & dosage (966) 966
breast-cancer (930) 930
breast neoplasms - metabolism (900) 900
medicine & public health (894) 894
analysis (851) 851
risk factors (850) 850
expression (838) 838
postmenopause (833) 833
abridged index medicus (827) 827
prevention (815) 815
aromatase inhibitors (786) 786
aged, 80 and over (781) 781
breast neoplasms - surgery (779) 779
endocrine therapy (777) 777
receptors, estrogen - metabolism (777) 777
prognosis (749) 749
breast neoplasms - mortality (740) 740
dosage and administration (709) 709
dose-response relationship, drug (706) 706
drug administration schedule (703) 703
randomized-trial (694) 694
obstetrics & gynecology (691) 691
time factors (673) 673
menopause (665) 665
estradiol - pharmacology (660) 660
disease-free survival (641) 641
antineoplastic agents, hormonal - adverse effects (635) 635
endocrinology & metabolism (626) 626
combined modality therapy (615) 615
estrogen antagonists - pharmacology (609) 609
breast neoplasms - genetics (605) 605
follow-up studies (601) 601
anastrozole (584) 584
tamoxifen - analogs & derivatives (583) 583
neoplasm staging (577) 577
cyclophosphamide - administration & dosage (569) 569
estrogen-receptor (563) 563
antineoplastic agents - therapeutic use (557) 557
breast neoplasms - prevention & control (554) 554
tumors (538) 538
clinical trials as topic (537) 537
fluorouracil - administration & dosage (537) 537
trial (536) 536
oncology, experimental (534) 534
letrozole (530) 530
apoptosis (528) 528
biochemistry & molecular biology (525) 525
article (522) 522
breast neoplasms - therapy (518) 518
risk (514) 514
cell line, tumor (511) 511
cells (503) 503
aromatase inhibitors - therapeutic use (495) 495
carcinoma (481) 481
surgery (463) 463
receptors, estrogen - analysis (462) 462
estradiol (455) 455
survival analysis (454) 454
clinical trials (451) 451
gene expression (451) 451
cell biology (449) 449
survival (444) 444
randomized controlled trials as topic (441) 441
ovariectomy (438) 438
raloxifene (432) 432
adjuvant treatment (424) 424
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11358) 11358
Japanese (228) 228
French (100) 100
German (92) 92
Russian (45) 45
Italian (20) 20
Spanish (18) 18
Chinese (12) 12
Polish (9) 9
Hungarian (7) 7
Korean (5) 5
Portuguese (5) 5
Czech (4) 4
Danish (4) 4
Swedish (4) 4
Dutch (3) 3
Romanian (3) 3
Persian (2) 2
Hebrew (1) 1
Norwegian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 02/2015, Volume 26, Issue 2, pp. 313 - 320
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 1/2008, Volume 100, Issue 2, pp. 121 - 133
Background Docetaxel is more effective than doxorubicin for patients with advanced breast cancer. The Breast International Group 02-98 randomized trial tested... 
CANCER PATIENTS | 1ST-LINE TREATMENT | PHASE-II TRIAL | THERAPY | EPIRUBICIN | ONCOLOGY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | METHOTREXATE | COMBINATION CHEMOTHERAPY | FLUOROURACIL | CMF | Immunohistochemistry | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Tamoxifen - administration & dosage | Receptors, Progesterone - analysis | Antineoplastic Agents, Phytogenic - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Odds Ratio | Adenocarcinoma - chemistry | Doxorubicin - administration & dosage | Drug Administration Schedule | Estrogen Receptor Modulators - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Lymphatic Metastasis | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Methotrexate - administration & dosage | Aged | Adenocarcinoma - surgery | Breast cancer | Dosage and administration | Drug therapy | Comparative analysis | Doxorubicin | Docetaxel | Clinical trials | Comparative studies | Chemotherapy | Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 9, pp. 840 - 849
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 8/2008, Volume 100, Issue 15, pp. 1058 - 1067
Background Current recommendations that cancer patients receive a maximum cumulative dose of 900 mg/m2 epirubicin are based on the risk of epirubicin-mediated... 
APOPTOSIS | PHARMACOKINETICS | ONCOLOGY | CYCLOPHOSPHAMIDE | TAMOXIFEN | DOXORUBICIN | CARDIOVASCULAR-DISEASE | CARDIOTOXICITY | RADIOTHERAPY | CONGESTIVE-HEART-FAILURE | CHEMOTHERAPY | Anthracyclines - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Heart Failure - physiopathology | Antibiotics, Antineoplastic - adverse effects | Epirubicin - administration & dosage | Tamoxifen - administration & dosage | Cisplatin - administration & dosage | Fluorouracil - administration & dosage | Adult | Female | Retrospective Studies | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Heart - physiopathology | Severity of Illness Index | Disease Susceptibility | Drug Administration Schedule | Risk Factors | Proportional Hazards Models | Neoplasm Recurrence, Local - diagnosis | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Vindesine - administration & dosage | Denmark - epidemiology | Heart - drug effects | Breast Neoplasms - mortality | Methotrexate - administration & dosage | Aged | Heart Failure - chemically induced | Epirubicin - adverse effects | Breast cancer | Dosage and administration | Epirubicin | Drug therapy | Risk factors | Heart | Chemotherapy | Side effects | Toxicity | Oncology | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 02/2016, Volume 108, Issue 2, p. djv318
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9707, pp. 2055 - 2063
Summary Background Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of... 
Internal Medicine | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | THERAPY | CYCLOPHOSPHAMIDE | METHOTREXATE | ANTAGONISM | CARCINOMA | FLUOROURACIL CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Lymph Nodes - pathology | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Alkylating - administration & dosage | Tamoxifen - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Receptors, Progesterone - analysis | Fluorouracil - administration & dosage | Postmenopause | Adult | Female | Chemotherapy, Adjuvant | Doxorubicin - administration & dosage | Antineoplastic Agents, Hormonal - administration & dosage | Lymphatic Metastasis | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Adenocarcinoma - mortality | Adjuvant treatment | Breast cancer | Dosage and administration | Research | Drug therapy | Tamoxifen | Health aspects | Cancer | Heart failure | Chemotherapy | Womens health | Mortality | Clinical trials | Mammography | Radiation therapy | Cancer therapies | Tumors | Toxicity | Leukemia | Congestive heart failure | Doxorubicin | Subgroups | Rank tests | Randomization | Motivation | Registration | Mastectomy | Thromboembolism | Neutropenia | Review boards | Regression analysis | Patients | Survival | Post-menopause | Stomatitis | Cyclophosphamide | Anthracycline | Breast | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 8, pp. 766 - 776
This study of adjuvant hormonal therapy in postmenopausal women with hormone-receptor–positive early breast cancer showed that disease-free survival was... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | EXEMESTANE | CONTINUED TAMOXIFEN | ADJUVANT ENDOCRINE THERAPY | RANDOMIZED-TRIAL | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | ANASTROZOLE | Aromatase Inhibitors - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Fractures, Bone - epidemiology | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Incidence | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Postmenopause | Female | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Nitriles - adverse effects | Women | Care and treatment | Usage | Breast cancer | Tamoxifen | Comparative analysis | Health aspects | Drug therapy | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus | Hormonal | Breast Neoplasms | epidemiology | administration & dosage | Triazoles | Nitriles | Adjuvant | drug therapy | Antineoplastic Agents | Local | prevention & control | Aromatase Inhibitors | Chemotherapy | Fractures | adverse effects | Bone | Neoplasm Recurrence | Cancer and Oncology | Kaplan-Meiers Estimate | Cancer och onkologi
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 01/2019, Volume 75, Issue 1, pp. 133 - 133
Journal Article